Date: Jun 2, 2011

Location: Slater, IA, US

Division: Syngenta Business Service (SBS)
Function: Information Systems
City: Slater
State/Province: Iowa [IA]
Position Title: Business Analyst-Quantitative Genetics
Job ID: 2297

Role Purpose/Accountabilities:
Role purpose

- Responsible for investigating business processes related to marker assisted breeding, identifying options for improving business processes and bridging the needs of the business with the use of IT
- Provide analytical skills for Research and Development Information Systems (RDIS) projects in the area of marker assisted breeding, including requirements analysis, and business process analysi
- Responsible for identifying and articulating current and future Information Systems (IS) demand arising in the R&D business in the area of marker assisted breeding

Accountabilities:

- Investigate IS requirements on project basis; map or propose business process for specific IS need.
- Own deliverables (as appropriate) such as business process maps, requirements documentation and user acceptance specifications.
- Help support strategic initiatives such as landscapes, roadmaps, and business process models in the context of the IS need and as required by the management
- Provide a key liaison into the business during the completion of projects and provide continuity in the development of future systems landscape in the area.
- Provide resource and expertise in the areas of requirements gathering, stakeholder management and business process design and re-engineering for large projects


Knowledge, Skills & Experience:

Critical knowledge:

- A good grasp of the culture and working practices of Molecular Marker Assisted Breeding and Marker: Trait association methods
- A working familiarity of business processes and science of Marker Assisted Breeding and Marker: Trait association methods.
- QTL mapping, Association mapping, Bulk Segregant analysis, Genome Wide Association mapping using Next gen sequence analysis
- Marker assisted trait selection, QTL selection, recurrent selection and back crossing.
- Able to interact with genetics, genomics and bioinformatics scientists
- Genotypic, phenotypic and environmental data integration
- A working familiarity with describing and documenting business processes
Critical experience

- At least 4 years experience in working within or close to R&D within Syngenta or other life science organizations.
- Minimum Masters degree in genetics, molecular biology, biological sciences, or masters degree in IS with strong biological background
- Experience or aptitude in working on information systems and/or information management processes associated with a commercial organisation.

Critical technical, professional and personal capabilities:
- Strong personal presence and ability to influence at senior levels.
- Strong networking skills across cultures
- Excellent communication skills and capabilities
- Compelling vision of what business and IS success look like and the ability to communicate this widely
- Ability to challenge requests for new solutions to ensure investments are made in the right areas to drive strategic growth

Critical Success Factors & Key Challenges:
- Perform set of tasks and techniques to work as a liaison among stakeholders in order to understand the science, structure, policies, and operations of an Syngenta’ Marker Assisted Breeding Program, and to recommend IT/ IS solutions that enable the Syngenta to achieve its goals
- Work with stakeholders to establish key relationships within Syngenta to increase knowledge of the business, maintain appropriate governance and understand wants and needs to provide effective change
- Develop and participate in the governance of Quantitative Genetics IS area and provide a key liaison point into the business during the completion of the design and as a point of continuity through the build, test and roll-out phases of RDIS projects
- Balance conflicting interests (e.g.of different business units) to come to a harmonized design


Additional Information:

- All applicants must be eligible to work in the US.

Posted: June 5, 2011

Medical Writer- Connecticut -Medical Education/ Medical Communications

My client a very strong healthcare communications companies in the local Connecticut area is actively seeking an entry level Medical Writer. This is a position for individuals who have recently completed a PhD, MD or PharmD degree, and are looking for alternative avenues other than research/working as a clinician or pharmacy. Current Postdoc fellows looking to transition from the lab to medical writing will also be considered.

Individuals qualifying for this position will have the following qualifications:

•An advanced degree in the life sciences, PhD, MD or Pharm D degree
•All therapeutic experience considered
•Excellent communication skills both written and verbal as you will be interacting on a regular basis with staff, clients and industry professionals
•Strong time and project management skills
•Knowledge of AMA writing style
•Prior writing experience
•Hands on Medical writing experience: original and review manuscripts, advisory boards, executive summaries, abstracts, posters, oral presentations, executive summaries, and publication plans
•Experience in all areas will be considered i.e. (Oncology, Diabetes, R/A Hematology, etc). •Excellent computer skills: Word, PowerPoint, Excel, and other industry software

Please send a word copy of your resume to
alex@libertyjobs.com today for consideration and more details on the company. All information is strictly confidential.

Alex Showers
484-567-2087
alex@libertyjobs.com

------------------------------------------------------------------------------------------------

Posted: June 9, 2011

My client an excellent medical communications company in the local Philadelphia suburbs is actively seeking Medical Writers, ideally with research, postdoc fellowship, clinical or industry writing experience. Salary and position level depend upon the level of experience as positions exist for entry level through to experienced writers.

****ENTRY LEVEL MUST WORK ON SITE**** Some flexibility possible for experienced writers

This is an excellent growth opportunity for a recent postdoc with publication experience looking to gain industry medical writing experience. This is the perfect role for someone who enjoys writing & science and communicating information to healthcare professionals is seeking career advancement, growth and increased responsibility.

Requirements:
•Qualified individuals will have recently completed PhD research or in a postdoc fellowship, or individuals with industry Medical Education/Publications/Medical Communications writing/director experience
•Advanced Degree- PhD, MD, PharmD degree is a must
•Strong scientific acumen and ability to quickly learn new therapeutic areas
•Experience in the area of Oncology is a plus, all areas considered
•Excellent communications skills both written and verbal
•Previous medical writing experience (industry or academia) that would include original and review manuscripts, abstracts, posters, oral presentations, executive summaries, and publication plans.

Please send a word copy of your resume to
alex@libertyjobs.com. All information is strictly confidential and will not be sent anywhere prior to speaking with you first.

Alex Showers
Liberty Personnel Services
484-567-2087
alex@libertyjobs.com

American Journal Experts, LLC is the leader in author-oriented solutions in the world of academic publishing. AJE provides language editing, translation, and review services to international customers and publishing partners. We are looking for highly motivated, detail-oriented individuals to fill the role of Managing Editor. This is a great opportunity to get involved with a fast-growth start-up. The position is full-time and is located in Durham, North Carolina.

The managing editors at American Journal Experts are responsible for maintaining the high quality of our edits, while managing a team of contract editors and serving as the liaison between the editor and the customer. The most important ME task is approving edits, which consists of ensuring the performance of the contract editors in terms of language editing. In addition, each ME manages a team of contract editors and provides them with regular feedback. MEs also respond to occasional editor and customer questions, and handle the occasional customer complaint.

MEs work from home, with two team meetings each month at our Durham offices. Because we offer 24/7 service to our customers, ME working schedules extend into holidays and weekends. The AJE work environment is stimulating and dynamic, and AJE managing editors are hardworking and fun to work with. We are looking for managing editors who are independent, intelligent, flexible, and team-oriented leaders, as well as being self-motivated with good time management skills. A Ph.D. is preferred, and relocation to North Carolina is required.

Apply for this position

American Journal Experts (AJE) is the leader in author-oriented solutions in the world of academic publishing. AJE provides language editing, translation, and review services to international customers and publishing partners. We are looking for highly motivated, detail-oriented individuals to fill the role of Managing Translator for the Portuguese and/or Spanish translation arms of the company. This is a great opportunity to get involved with a fast-growth start-up. The position is full-time and is located in Durham, North Carolina.

The Managing Translators at AJE are responsible for maintaining the high quality and accuracy of our translations, while managing a team of contract translators and serving as the liaison between the translator and the customer. To perform these tasks effectively, Managing Translators must be fluent and have research experience in both languages, be fair and honest managers, and be effective communicators. The Managing Translator is the core of AJE's translation service, and the quality the work performed by the person in this position has the largest influence on the success of our service.

This position involves work from home with the option to work in our office, as well as two or more required team meetings each month at our Durham office. Because we offer 24/7 service to our customers, work schedules do extend into holidays and weekends at times. The AJE work environment is stimulating and dynamic, and our team is filled with people who are hardworking and fun to work with. We are looking for employees who are independent, intelligent, flexible, and team-oriented leaders, as well as being self-motivated with good time management skills. A PhD is preferred, and relocation to North Carolina is required.

Job Requirements

• Fluency in Portuguese, Spanish and English, preferably including technical/research experience in both languages
• MD, PhD, or Masters degree
• Familiarity with Microsoft Word
• Strong time management skills
• Ability to work independently

AJE is dedicated to helping researchers worldwide to get published in English-language journals. We are passionate about eliminating barriers and accelerating global discovery. To become a part of our mission and join our team, please fill out your information online at https://www.journalexperts.com/careers/login.

Apply for this position

The Helen Hay Whitney Foundation supports early postdoctoral research training in all basic biomedical sciences. To attain its ultimate goal of increasing the number of imaginative, well-trained and dedicated medical scientists, the Foundation grants financial support of sufficient duration to help further the careers of young men and women engaged in biological or medical research.

Eligibility

Candidates who hold, or are in the final stages of obtaining a Ph.D., M.D., or equivalent degree and are seeking beginning postdoctoral training in basic biomedical research are eligible to apply for a fellowship. The Foundation accepts applications from candidates who have no more than one year of postdoctoral research experience at the time of the deadline for submitting the application (July 14), and who have received a PhD (or D.Phil. or equivalent) degree no more than two years before the deadline, or an M.D. degree no more than three years before the deadline.

Fellowships may be awarded to US citizens planning to work in laboratories either in the US, Canada, or abroad and also to foreign citizens for research in laboratories in the US only. We expect that most applicants will reside in North America at the time of application. Foreign Students will need to obtain appropriate visa documentation, as required by US Immigration.

Stipend and Expense Allowance

The current stipend and expense allowance is:

	Stipend	Research Allowance
1st year	$48,000	$2,500
2nd year	$49,000	$2,500
3rd year	$50,000	$2,500

There is a research allowance of $2,500 paid annually to the laboratory. It is to be used at the discretion of the Fellow with no deductions for institutional overhead, registration fees, or taxes. This money is to be used for research expenses, such as lab supplies, computers, etc. If the Fellow wishes, this money may be used, in part or entirely, to help defray the cost of the Fellow’s health insurance premiums. The Fellow determines how this research allowance will be spent. Payment of the research allowance will be made on the fellowship activation date, and annually thereafter.

There is a Dependent Child Allowance of $1,000 per annum for each child. There is no allowance for a spouse. If a fellowship is awarded and the Fellow advises us that he or she is eligible for the Dependent Child Allowance, we will then request a copy of the birth or adoption certificate(s). Payment of the child allowance will be made on the fellowship activation date, and annually thereafter.

Competition

Competition for the Helen Hay Whitney fellowships is intense. Less than 5% of those who apply to us receive awards. Please note that because of the volume of applications received, the Foundation is unable to provide critiques of unsuccessful proposals.

Applications

Applications are to be filled out and submitted online at www.hhwf.org. Applications must be received by The Helen Hay Whitney Foundation no later than 5:00pm EST, July 14, 2011. Late applications will not be considered.

Click Here To Apply Online

Lower levels of spending growth in the United States, the continuing impact of patent expirations in developed markets, strong growth in emerging markets, and policy-driven changes in certain countries relating to drug reimbursement are key factors that will influence pharmaceutical industry growth during the next five years.

The global pharmaceutical market is expected to reach $1 trillion by 2014 and nearly $1.1 trillion by 2015, according to the IMS Institute for Healthcare Informatics. The market will increase at a compound annual growth rate (CAGR) of 3–6% during the next five years, slowing from the 6.2% annual growth rate that occurred during the past five years. Absolute global-spending growth is expected to be $210–240 billion between 2011 and 2015 compared with $251 billion between 2006 and 2010. Removing the effect of exchange-rate fluctuations, absolute global-spending growth will be $230–250 billion on a constant dollar basis compared with $228 billion in the previous five years. For purposes of this analysis, the pharmaceutical market includes all types of biopharmaceuticals, including biologics, over-the-counter drugs, and traditional medicines distributed and administered through regulated delivery systems, such as pharmacies, hospitals, clinics, physician offices, and mail order. Spending figures are reported at ex-manufacturer estimates that do not reflect off-invoice discounts and rebates.

“The future level of spending on medicines has striking implications for healthcare systems and policy makers across the developed and emerging economies,” said Murrary Aitken, executive director of the IMS Institute for Healthcare Informatics, in a May 18, 2011, IMS press release. “Past patterns of spending offer few clues about the level of expected growth through 2015. There are unprecedented dynamics at play, which are driving rapid shifts in the mix of spending by patients and payers and between branded products and generics and across both developed and pharmerging markets.”

Declining growth in developed markets
The US share of global pharmaceutical spending will decline from 41% in 2005 to 31% in 2015 while the share of spending from the top five European national markets (i.e., Germany, France, Italy, Spain, and the United Kingdom) will decline from 20% to 13% during the same period. Meanwhile, 17 high-growth emerging markets, led by China, will contribute 28% of total spending by 2015, up from only 12% in 2005, according to IMS. The next five years also will see an accelerating shift in spending toward generic drugs, whose share of of pharmaceutical spending will rise to 39% in 2015, up from 20% in 2005.

On a geographic basis, the pharmaceutical market for developed nations was valued at $587.1 billion in 2010. The US was the single largest national market at $310.6 billion. The pharmaceutical market in the top five European countries (i.e., Germany, France, Italy, Spain, and the United Kingdom) was $147.4 billion in 2010 and $96.5 billion in Japan in 2010, according to IMS. Slowing pharmaceutical market growth is forecasted for the US, Europe, and Japan. In the US pharmaceutical market, CAGR (in $US at constant exchange rates) was 4.5% between 2006–2010, and growth is projected to slow to a CAGR of only 0–3% between 2011 and 2015, according to IMS. In the top five European countries (i.e., Germany, France, Italy, Spain, and the United Kingdom), CAGR (in $US at constant exchange rates) was 4.1% between 2006–2010, and growth is expected to slow to a CAGR of 1–4% between 2011 and 2015. In Japan, CAGR (in $US at constant exchange rates)) was 2.6% between 2006–2010, and CAGR of 2–5% is projected between 2011 and 2015, according to IMS.

Factors influencing global pharmaceutical demand
Generic-drug incursion. The level of patient expiries will continue to have a strong effect on the global pharmaceutical market. Spending for branded products in developed markets will remain at the same level in 2015 as it was in 2010, according to IMS. Globally, market share for branded medicines, which fell from 70% in 2005 to 64% in 2010, is expected to decline further through 2015, to 53%. While growth for branded products in the emerging markets will be robust, 80 cents of every dollar spent on medicines in emerging markets in 2015 will be for generic drugs, according to IMS. Global generic-drug spending was estimated at $234 billion in 2010, up from $124 billion in 2005. Generic-drug spending in 2015 is expected to be between $400–430 billion, 70% of which will be outside developed markets.

Overall, expiring patents for branded products will yield $98 billion in net savings to payers in developed countries through 2015, compared with $54 billion in savings realized in the five years to 2010, according to IMS. Patent expiries will save payers $120 billion by 2015, offset by $22 billion of expected generic-drug spending for these medicines. Among developed markets, the US will have the largest expansion of generic-drug spending. Japan will continue to have the lowest share despite significant policy incentives to increase generic-drug prescribing and dispensing.

Emerging-market growth. During the next five years, growth in emerging markets, defined by IMS as the “pharmerging markets” are expected to nearly double their spending on medicines to between $285 billion and $315 billion, compared with spending of $151 billion in 2010, according to IMS. Pharmerging countries are defined as those countries with absolute pharmaceutical pending growth of greater than $1 billion during 2011–2015 and that have gross domestic product per capita of less than $25,000 on a purchase-price parity basis. Using that criteria, these countries include: China (classified as Tier 1); Brazil, Russia, and India (classified as Tier II); and Mexico, Turkey, Poland, Venezuela, Argentina, Indonesia, South Africa, Thailand, Romania, Egypt, Ukraine, Pakistan, and Vietnam (classified as Tier III).

Gains in pharmaceutical spending in the pharmerging markets will be driven by overall strong economic growth and governments’ commitment to expand healthcare access. IMS projects that by 2015, the pharmerging countries will become the second largest geographic segment globally in spending on medicines, surpassing Germany, France, Italy, Spain, and the United Kingdom combined and approaching US levels. Pharmerging countries are expected to nearly double their pharmaceutical spending by $150 billion by 2015. Of the total increase in spending, approximately 20% will come from branded products.

Breaking down growth in emerging markets, China’s pharmaceutical market was valued at $41.1 billion in 2010. The pharmaceutical market in Tier-II emerging markets (Russia, India, and Brazil) was $48.4 billion (i.e., Brazil at $22.9 billion, India at $12.3 billion, and Russia at $13.6 billion), and the pharmaceutical market in Tier-III emerging markets (Mexico, Turkey, Poland, Venezuela, Argentina, Indonesia, South Africa, Thailand, Romania, Egypt, Ukraine, Pakistan, and Vietnam) was $60.6 billion in 2010, according to IMS. In China’s pharmaceutical market, CAGR (in $US at constant exchange rates) was 23.9% between 2006–2010, and a CAGR of 19–22% is projected between 2011 and 2015, according to IMS. In the Tier-II emerging markets, CAGR (in $US at constant exchange rates) was 15.9% between 2006–201 (Brazil at 14.1%, India at 15.7%, and Russia at 20.0%). Growth is expected to continue to be roubust with a collective CAGR for Tier-II countries of 11–14% between 2011 and 2015. In Tier-III emerging markets, CAGR (in $US at constant exchange rates) was 11.8% between 2006–2010, and growth is expected to increase at a CAGR of 10–13% between 2011 and 2015, according to IMS.

Healthcare spending. Several policy moves will affect healthcare spending during the next five years. In the US, healthcare reform as made through the passage of the Affordable Care Act is expected to expand health insurance coverage to 25–30 million people in America. Price controls in China are designed to achieve universal health coverage. Japan will implement its first price cut under its new protected innovative products policy. In Europe, price reductions for generic drugs are expected in Spain and Italy, and mandatory cost-benefit evaluations for new products are slated for Germany. Additionally, rebates and discounts, which are not reflected in IMS’s market data, are being applied more extensively by both public and private payers, particularly in the US, France, and Germany. IMS estimates the amount of these off-invoice discounts in 2010 at between $60 billion and $65 billion and expects the value of these discounts to increase to between $65 billion and $75 billion by 2015.

Biosimilars. Biosimilars are a small, but growing, part of the pharmaceutical market. By 2015, IMS expects spending on biosimilars to reach $2 billion annually, or approximately 1% of total global spending on biologics. New biosimilars are expected to enter the US and European markets by 2014, according to IMS, which will increase spending on biosimilars by $311 million compared with 2010 levels.

Therapeutic classes
On a therapeutic-class basis, oncology is expected to remain the leading therapeutic class, but with slowing growth of 5–8% between 2011 and 2015 as existing targeted therapies already have been widely adapted. Spending on diabetes treatments between 2011 and 2015 is projected to increase 4 to 7%, driven by the increase in the incidence of diabetes and the introduction of newer oral antidiabetic drugs. Growth for respiratory drugs, specifically for asthma and chronic obstructive pulmonary disease treatments, is expected to slow to 2 to 5% between 2011 and 2015, and spending on lipid regulators will decline from $37 billion in 2010 to $31 billion in 2015, according to IMS.

Jun 2, 2011
By: Patricia Van Arnum
Pharmaceutical Technology

A group of Republican lawmakers has asked appropriators to avoid making deep cuts to the budget of the National Institutes of Health.

The request that NIH be spared highlights the difficult choices facing the GOP as it moves from writing a budget to wringing out cuts from 13 different appropriations measures.

Casting a vote to reduce the nation’s deficit is easy. Cutting programs that are seeking a cure for cancer is more difficult.

“It’s very tough,” said Rep. Brian Bilbray (R-Calif.), one of 12 Republicans pressing for NIH funding to be kept up.

NIH took a $321 million cut in the 2011 budget process, and health advocates believe it could face a much bigger reduction as lawmakers seek $18 billion in cuts to a spending measure for the departments of Health and Human Services, Labor and Education.

“They’ll have trouble getting the cuts anywhere else,” Atul Grover, chief advocacy officer for the Association of American Medical Colleges, told The Hill this week.

The cuts will feel more severe at NIH after the agency benefited from the 2009 stimulus bill. Those remaining funds will run out at the end of the year.

Given the 40 percent cuts being proposed to discretionary domestic spending programs, Bilbray said a call to keep NIH funding stable or to even increase it means other programs must take bigger hits.

Faced with a choice between NIH and public broadcasting, Bilbray said, “I’m sorry Big Bird. I’m going with NIH.”

Republicans are already starting to feel the heat as budget talks wade into specifics.

The GOP moved its first two spending measures through committee on Tuesday, chopping funding for the Federal Emergency Management Agency (FEMA) and firefighter training and assistance grants, among other things.

Democrats accused the GOP of cutting disaster aid. Republicans said they were cutting grants that communities get before a disaster, and that FEMA had done a poor job of prioritizing funds.

The fight over Rep. Paul Ryan’s (R-Wis.) budget and its proposed reforms of Medicare is the main event, but Democrats are looking to pounce on Republican cuts to other programs as the appropriations process unfolds.

Republicans supporting the NIH say it represents the nation’s best hope for “finding cures, improving treatment and gaining a better understanding of the diseases and conditions that affect millions of Americans.”

“We urge you to consider the wide-ranging, positive effects of investment in research on health and the economy. We appreciate your consideration of our request,” Bilbray and 11 other Republicans wrote to Rep. Denny Rehberg (R-Mont.), the chairman of the subcommittee that handled NIH’s budget.

Besides Bilbfray, the letter was signed by Reps. Dave Reichert (Wash.), Jim Gerlach (Pa.), Todd Platts (Pa.), Tom Petri (Wis.), Steve Stivers (Ohio), Aaron Schock (Ill.), Judy Biggert (Ill.), Bill Johnson (Ohio), Pete King (N.Y.), Elton Gallegly (Calif.) and Nan Hayworth (N.Y.), along with Democratic Rep. Gerry Connolly (Va.).

The NIH also has friends in the Senate. It was set to take a $1.6 billion cut in funding for 2011 before Senate negotiators winnowed that down to $320 million.

Winning further reprieves won’t be easy, given the deficit-cutting mood in Washington. Prominent supporters of the NIH such as Sen. Arlen Specter (D-Pa.) are no longer in Congress. And with the rise of the Tea Party, Sen.

Orrin Hatch (R-Utah) and other GOP backers must worry about being seen as soft on fiscal issues.

“I want to thank you, as members of the Senate, for sparing NIH from deeper cuts in the final fiscal year 2011 continuing resolution,” NIH Director Francis Collins said in testimony earlier this month.

He noted that other programs and functions were cut much more deeply.

By Ian Swanson - 05/27/11 06:11 AM ET

Senior Science Writer

Job Category: Full-time/Exempt

Department/Division: Publications Department / Publishing and Product Development

Reports To: Executive Editor, Cancer Discovery

Location: Philadelphia, PA

Organization Profile:

The American Association for Cancer Research (AACR), with nearly 33,000 members, is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research. The AACR publishes seven peer-reviewed scientific journals and a magazine; convenes topical scientific conferences and an annual meeting that draws more than 18,000 participants; offers workshops, fellowships and grants; raises public awareness of the progress in and cause for hope in cancer research; and advocates for strong federal research funding.

As part of its ongoing commitment to providing comprehensive information to the science community, the AACR has developed an important new journal, Cancer Discovery. This high-impact publication presents peer-reviewed articles describing major advances in research and clinical trials. Cancer Discovery is an essential information resource that offers original research articles, review articles, news, perspectives and commentaries, and Research Watch summaries of noteworthy journal articles. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies.

Job Summary:

The senior science writer will oversee the Research Watch section and features of Cancer Discovery. This includes coordinating input received from scientific editorial board members, writing and editing summaries and features, and ensuring consistently high-quality content across the breadth of cancer science and medicine. Research Watch summaries will be reported weekly through the online journal, later moving to online posting more frequently. Selected summaries will be published in and/or linked to the monthly print version. In addition to the Research Watch section, the successful candidate will work with the journal’s executive editors and journal news staff to develop special features.

The senior science writer will report to a Cancer Discovery executive editor and will be a key member of the senior editorial team.

Major Duties and Responsibilities:

• Surveys select journals for potential content for coverage
• Researches, writes, produces and edits Research Watch summaries
• Establishes, monitors and reports on measurements for progress and informed decision-making
• Sets targets for continuous improvement of content coverage, quality and turnaround
• Trains and supervises an in-house science writer
• Manages multiple projects and delivers them according to prescribed deadlines
• Works with the journal’s editorial, marketing and production teams, as well as AACR’s Communications, Policy and Program departments
• Represents the journal at conferences and meetings

Qualifications and Competencies:

• Five years of experience writing scientific articles in the life sciences, as well as a history of effectively managing staff and freelance workers
• Demonstrated success delivering accurate, high-quality, timely stories with scientific content
• Ability to communicate directly with researchers and to translate technical scientific content to scientists working in other disciplines
• Understanding of organization, structure and ethics of electronic and print media, journalistic techniques, terminology and style, as they relate to scientific content
• Outstanding management and leadership skills with the ability to maneuver and adapt practices in response to an ever-changing work environment
• Excellent verbal and written communication skills
• High level of motivation, initiative and commitment to researching and delivering scientific content
• Highly developed interpersonal and diplomatic skills; ability to exercise sound judgment in decision-making
• Strong project management skills and the ability to manage multiple priorities
• Ability to collaborate with department, staff and others involved in the work of the journal

Education and Training:

• A master’s degree in a life science, journalism or scientific writing
• Ph.D. or M.D. a plus

How to Apply

This position offers a competitive salary and an excellent benefits package. To apply, please send a letter of interest and curriculum vitae to:

Human Resources
P.O. Box 40138
Philadelphia, PA 19106
e-mail: humanresources@aacr.org
fax: 215-440-1045

Science Writer

Job Category: Full-time/Exempt

Department/Division: Publications Department / Publishing and Product Development

Reports To: Executive Editor, Cancer Discovery

Location: Philadelphia, PA

Organization Profile:

The American Association for Cancer Research (AACR), with nearly 33,000 members, is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research. The AACR publishes seven peer-reviewed scientific journals and a magazine; convenes topical scientific conferences and an annual meeting that draws more than 18,000 participants; offers workshops, fellowships and grants; raises public awareness of the progress in and cause for hope in cancer research; and advocates for strong federal research funding.

As part of its ongoing commitment to providing comprehensive information to the science community, the AACR has developed an important new journal, Cancer Discovery. This high-impact publication presents peer-reviewed articles describing major advances in research and clinical trials. Cancer Discovery is an essential information resource that offers original research articles, review articles, news, perspectives and commentaries, and Research Watch summaries of noteworthy journal articles. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies.

Job Summary:

The science writer will write and edit summaries for the Research Watch section and other featured content of Cancer Discovery. Research Watch summaries will be reported weekly through the online journal, later moving to online posting more frequently. Selected summaries will be published in and/or linked to the monthly print version. In addition to the Research Watch section, the successful candidate will work with the journal’s executive editors and journal news staff to develop special features. The science writer will report to the senior science writer.

Major Duties and Responsibilities:

• Surveys select journals for potential content for coverage in Research Watch section
• Researches, writes, produces and edits Research Watch summaries

Qualifications and Competencies:

• Three years of experience writing scientific articles in the life sciences
• Demonstrated success delivering accurate, high-quality, timely stories with scientific content
• Ability to communicate directly with researchers and to translate technical scientific content to scientists working in other disciplines
• Understanding of organization, structure and ethics of electronic and print media, journalistic techniques, terminology and style, as they relate to scientific content
• Excellent verbal and written communication skills
• High level of motivation, initiative and commitment to researching and delivering scientific content

Education and Training:

• A bachelor’s degree in a life science, journalism or scientific writing

How to Apply:

This position offers a competitive salary and an excellent benefits package. If you are interested in being considered for this position, please send a letter of interest along with your most current curriculum vitae, salary history and writing samples to:

American Association for Cancer Research, Inc.
Human Resource Department
P.O. Box 40138
Philadelphia, PA 19106
e-mail: humanresources@aacr.org
fax: 215-440-1045

Seeking a high-energy, recent Ph.D or post-doc for a Field Application Science role with a leading life science/diagnostics company. MUST have strong working knowledge of qPCR and RT-PCR.

Great company, great salary, great benefits. Must be enthusiastic and willing to interface with customers regularly. Appx. 40% travel. Can be located in Boston or NY.

If you are interested in pursuing this opportunity to go from academia into industry, please call 248-629-7210 and/or e-mail a resume to daniellep@k2search.com